The stock of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) hit a new 52-week low and has $98.56 target or 8.00% below today’s $107.13 share price. The 6 months bearish chart indicates high risk for the $6.65 billion company. The 1-year low was reported on Nov, 2 by Barchart.com. If the $98.56 price target is reached, the company will be worth $532.00M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 386,919 shares traded hands. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) has declined 15.82% since March 31, 2016 and is downtrending. It has underperformed by 18.34% the S&P500.
Analysts await Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) to report earnings on November, 14. They expect $1.81 earnings per share, up 30.22% or $0.42 from last year’s $1.39 per share. JAZZ’s profit will be $112.42 million for 14.79 P/E if the $1.81 EPS becomes a reality. After $1.80 actual earnings per share reported by Jazz Pharmaceuticals plc – Ordinary Shares for the previous quarter, Wall Street now forecasts 0.56% EPS growth.
Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) Ratings Coverage
Out of 13 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 11 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 85% are positive. Jazz Pharmaceuticals has been the topic of 20 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Wednesday, June 29 by BMO Capital Markets. SunTrust upgraded Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) on Monday, April 25 to “Buy” rating. The firm has “Outperform” rating given on Friday, February 19 by Wells Fargo. Goldman Sachs initiated the stock with “Buy” rating in Monday, June 6 report. SunTrust maintained the stock with “Buy” rating in Thursday, June 2 report. Bernstein initiated the shares of JAZZ in a report on Wednesday, November 25 with “Market Perform” rating. On Wednesday, October 14 the stock rating was initiated by Northland Capital with “Outperform”. Deutsche Bank maintained Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) on Thursday, August 11 with “Buy” rating. Janney Capital initiated the stock with “Neutral” rating in Thursday, August 25 report. The stock of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) earned “Buy” rating by Mizuho on Friday, October 9.
According to Zacks Investment Research, “Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company’s goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. They apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.”
Insitutional Activity: The institutional sentiment increased to 1.25 in 2016 Q2. Its up 0.26, from 0.99 in 2016Q1. The ratio increased, as 43 funds sold all Jazz Pharmaceuticals plc – Ordinary Shares shares owned while 102 reduced positions. 61 funds bought stakes while 120 increased positions. They now own 52.76 million shares or 1.80% less from 53.73 million shares in 2016Q1.
Moreover, Franklin Street Advisors Nc has 0.19% invested in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) for 7,150 shares. Robeco Institutional Asset Management Bv last reported 0% of its portfolio in the stock. Moreover, Seven Eight Cap Lc has 0.02% invested in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) for 500 shares. Canada Pension Plan Invest Board reported 21 shares or 0% of all its holdings. Raymond James And Associate holds 0% or 2,497 shares in its portfolio. Avalon Advsrs Ltd Company owns 12,368 shares or 0.07% of their US portfolio. Clarivest Asset Limited Liability Corporation has 3 shares for 0% of their US portfolio. The Illinois-based Ubs Asset Americas has invested 0.02% in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Creative Planning holds 1,843 shares or 0% of its portfolio. Natl Bank Of America Corporation De, a North Carolina-based fund reported 169,829 shares. Mitsubishi Ufj Tru & Bk accumulated 0.04% or 123,922 shares. Timber Hill Ltd Limited Liability Company, a Connecticut-based fund reported 2,938 shares. First Republic Mgmt accumulated 0% or 1,446 shares. Mckinley Cap Mngmt Lc Delaware last reported 0.01% of its portfolio in the stock. Whittier Trust, a California-based fund reported 4,450 shares.
Insider Transactions: Since May 16, 2016, the stock had 3 insider purchases, and 19 sales for $9.29 million net activity. MILLER MICHAEL PATRICK had sold 100 shares worth $14,520 on Monday, May 16. McSharry Heather Ann had sold 685 shares worth $93,468. Winningham Rick E sold $86,373 worth of stock or 633 shares. The insider Mulligan Seamus sold $4.20 million. RIEDEL NORBERT G also sold $86,373 worth of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) on Monday, August 15. ENRIGHT PATRICK G had sold 633 shares worth $86,373. $86,373 worth of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) shares were sold by Sohn Catherine A..
JAZZ Company Profile
Jazz Pharmaceuticals Public Limited Company, incorporated on March 15, 2005, is a biopharmaceutical company. The Firm is focused on developing and commercializing products that address unmet medical needs. The Firm has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company’s lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company’s other product candidates include JZP-110 for treatment of excessive daytime sleepiness (EDS) in narcolepsy and EDS in patients with obstructive sleep apnea (OSA) and JZP-386 for the treatment of EDS in narcolepsy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.